CoChat

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2) are at particular cardiovascular risk. Fenofibrate’s safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate’s effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients (aged 50–75 years) with eGFR ≥30 mL/min/1.73 m2 were randomly allocated to a fixed dose of fenofibrate (200 mg daily) (n = 4,895) or placebo (n = 4,900) for 5 years. Baseline renal function (Modification of Diet in Renal Disease equation) was grouped by eGFR (30–59, 60–89, and ≥90 mL/min/1.73 m2). The prespecified outcome was total cardiovascular events (composite of cardiovascular death, myocardial infarction, stroke, and coronary/carotid revascularization). Serious adverse events and instances of ESRD (plasma creatinine >400 μmol/L, dialysis, renal transplant, or renal death) were recorded. Analysis was by intention to treat. RESULTS: Overall, fenofibrate reduced total cardiovascular events, compared with placebo (hazard ratio 0.89 [95% CI 0.80–0.99]; P = 0.035). This benefit was not statistically different across eGFR groupings (P = 0.2 for interaction) (eGFR 30–59 mL/min/1.73 m2: 0.68 [0.47–0.97], P = 0.035; eGFR ≥90 mL/min/1.73 m2: 0.85 [0.70–1.02], P = 0.08). ESRD rates were similar between treatment arms, without adverse safety signals of fenofibrate use in renal impairment. CONCLUSIONS: Patients with type 2 diabetes and moderate renal impairment benefit from long-term fenofibrate, without excess drug-related safety concerns compared with those with no or mild renal impairment. Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1109

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Percentage event rate of subtypes of vascular events and mortality within each category of eGFR. ■, 30–59 mL/min/1.73 m2; , 60–89 mL/min/1.73 m2; □, ≥90 mL/min/1.73 m2.
Figure 1 Percentage event rate of subtypes of vascular events and mortality within each category of eGFR. ■, 30–59 mL/min/1.73 m2; , 60–89 mL/min/1.73 m2; □, ≥90 mL/min/1.73 m2.CC BY-NC-ND · PubMed Central
Figure 2 HRs (95% CIs) for total CVD events, cardiovascular mortality, and total mortality risk by treatment allocation within different categories of eGFR. ■, relative weights of the outcome event in each group; ⋄, summary HR with 95% CI.
Figure 2 HRs (95% CIs) for total CVD events, cardiovascular mortality, and total mortality risk by treatment allocation within different categories of eGFR. ■, relative weights of the outcome event in each group; ⋄, summary HR with 95% CI.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Laboratoires Fournier, 2004, Fenofibrate Investigator’s Brochure

Cited by

See all 119

Metadata

Authors
Ting, R.-D., Keech, A. C., Drury, P. L., Donoghoe, M. W., Hedley, J., Jenkins, A. J., Davis, T. M. E., Lehto, S., Celermajer, D., Simes, R. J., Rajamani, K., Stanton, K., & on behalf of the FIELD Study Investigators
Affiliations
  • The University of Sydney (AU)
  • Auckland Diabetes Centre, Auckland, New Zealand
  • Department of Internal Medicine, Wairau Hospital, Blenheim, New Zealand
  • The University of Western Australia (AU)
  • Kuopio University Hospital (FI)
  • Royal Prince Alfred Hospital (AU)
  • Royal Perth Hospital (AU)
Corresponding author
  • Ting, Ru-Dee
  • Keech, Anthony C.
Venue
Diabetes Care
Published
2012-01-16
Volume
35
Issue
2
Pages
218-225
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2044493153
Cited by
119
References
36
Citations by year
2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 10 · 2016: 8 · 2015: 10 · 2014: 12 · 2013: 16 · 2012: 8
FWCI
8.91
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
Funders
  • European Society of Cardiology
  • Cardiac Society of Australia and New Zealand
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
fenofibrate, type 2 diabetes, renal dysfunction, estimated glomerular filtration rate, cardiovascular events, end-stage renal disease, serum creatinine, drug safety, lipid-lowering therapy, fieldwork, cardiovascular risk, renal dose adjustment, myocardial infarction, stroke, coronary revascularization, renal death, dialysis, kidney transplantation, cardiovascular mortality, serious adverse events
MeSH terms
Aged, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Fenofibrate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.